drugset / Trial / NCT02262767
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
RandomizedCrossoverDouble-blindBasic science
Summary
This study will test the hypothesis that PF-06649751 with continuous co-administration of trimethobenzamide hydrochloride (TMB) with will be safe and well tolerated. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration.
Timeline
- Start
- 2014-11
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tavapadon | Small molecule | 0.75 mg | Oral |
| Subject | Tavapadon | Small molecule | 3 mg | Oral |
| Subject | Tavapadon | Small molecule | 4.5 mg | Oral |
| Subject | Tavapadon | Small molecule | 9 mg | Oral |
| Background | Trimethobenzamide | Small molecule | — | — |
Indications
No indication recorded.